A "Living Pharmacy" That Makes Antibodies Inside the Body: What Transplant Teams Should Know

What if instead of giving a patient a biologic every few weeks, we implanted a tiny "pharmacy" that manufactured the medication inside their body for a year?

That's the idea behind new work from Rice University, published October 2 in Science Advances. Rice calls it a "living pharmacy." The paper itself uses the phrase "biologics factory." Before anything else: this is preclinical. The results come from mice and a nonhuman primate. It has not been tested in people.

What the study found

The team, led by Rice bioengineer Omid Veiseh, the paper's corresponding author, packed engineered cells inside a chemically modified alginate, a gel-like biomaterial designed to calm the local immune response. The cells make monoclonal antibodies continuously, right where they sit. According to the paper's abstract, here's what they showed:

  • One year, in mice. In immunocompetent mice, the lead formulation kept blood levels of an HIV-neutralizing antibody, 3BNC117, stable for one year.
  • Six months, in a primate. In a nonhuman primate, an implant under the skin kept ipilimumab levels stable for more than six months, with no detectable toxicity, anti-drug antibodies or adverse events. Exposure tracked with dose across three dose levels.
  • Thirteen antibodies. The same cell line was engineered to make 13 different monoclonal antibodies. A subset, including ipilimumab, pembrolizumab, adalimumab and PGT121, was delivered in animals over time. Rice says the antibodies kept their intended biological activity.
  • Retrievable. Inside a retrievable device, the implant could be taken out to stop treatment, or reimplanted to adjust the dose.

One detail matters for how we read the headline: the full year was shown in mice with one HIV antibody, not with every drug and not in the primate.

The big obstacle for implanted cells is the body's response. Rice explains that inflammation and scar tissue tend to build up around an implant, starving the cells and blocking the drug from getting out. The authors report that their alginate creates a local anti-inflammatory environment that cuts down on that scarring.

A company called Duracyte is developing the platform, and Rice says the implant is expected to "enter clinic in 2027." That's a goal, not a result.

Why this caught my attention

Transplant recipients already live on scheduled biologics. Belatacept (Nulojix) is a good example. Per the FDA label, it's a fusion protein built from part of CTLA-4 and part of a human antibody. It is not a monoclonal antibody. After the early phase, kidney recipients get it as an IV infusion every 4 weeks, starting at the end of week 16 after transplant. That's an infusion chair and an IV, month after month.

Belatacept wasn't part of this study, and the paper only made monoclonal antibodies. Still, it's hard not to picture what an implant like this could mean for patients who build their lives around infusion schedules.

Then there's rejection. Anything foreign we put in the body has to survive the immune system, and in transplant we know that problem well. The paper doesn't describe the implant in transplant terms, and neither the abstract nor Rice's release mentions transplant or immunosuppression. But the paper's reference list does point back to decades of encapsulation work with pancreatic islet cells, including alginate-encapsulated donor islets in macaques. It's an old idea in our field: protect donor cells with a barrier instead of with drugs alone.

Open questions for transplant teams

  • Could a platform like this ever make fusion proteins like belatacept, not just monoclonal antibodies? Rice suggests the cells could be engineered to make different proteins, but that hasn't been shown for transplant drugs.
  • How would implanted cells behave in someone already on immunosuppression? This study doesn't answer that.
  • Being able to take the implant out matters. Anyone who has needed to stop a drug quickly knows why.
  • For those of us in procurement: if these devices ever reach patients, how would we document one in a potential donor's history, and would it affect evaluation?

What I'll be watching

Whether this makes it into human studies, what the first patients look like, and how long the cells really last in people. Animal results often don't carry over, so I'm keeping my expectations measured. But the idea of a drug made inside the body, under our control, is worth paying attention to.

Sources

Back to blog